Related Experiment Video
Updated: Jan 4, 2026
Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
Published on: May 9, 2025
Advances in Engineering Cells for Cancer Immunotherapy
Xiao Xu1, Teng Li1, Shiyang Shen1
1State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, China Pharmaceutical University, Nanjing 210009, China.
Engineered cells, including CAR T-cell therapy, are advancing cancer immunotherapy by enhancing tumor cell killing and reducing side effects. This review summarizes progress and future directions in cell-based cancer treatments.
Area of Science:
- Oncology
- Immunology
- Biotechnology
- Nanomedicine
Background:
- Cancer immunotherapy harnesses the immune system to eliminate malignant cells.
- Established approaches include T-cell transfer (e.g., CAR T-cell therapy), antibody therapies (e.g., immune checkpoint blockade), and cytokine therapies.
Purpose of the Study:
- To review recent advancements in engineering cells for cancer immunotherapy.
- To discuss the future prospects of engineered cell-based cancer therapies.
Main Methods:
- Summary of biologically, chemically, and physically engineered cell strategies.
- Inclusion of bioinspired and biomimetic nanomedicines for enhanced immunotherapy.
Main Results:
- Engineered cell therapies demonstrate enhanced antitumor efficacy.
- These advanced therapies show potential for reduced side effects compared to conventional treatments.
Conclusions:
- Engineering cells represents a significant frontier in developing novel cancer immunotherapies.
- Continued research in this area promises more effective and safer cancer treatment options.
More Related Videos
11:08Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...